Exchange: NASDAQ·Updated 07:49 PM EST

VVOS News

News
all
press releases
Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript
Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript...
SeekingAlpha
Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript
Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript...
SeekingAlpha
More News
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +76.67% and +17.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Prelude Therapeutics (PRLD) delivered earnings and revenue surprises of +14.29% and +12.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Journey Medical (DERM) delivered earnings and revenue surprises of -66.67% and -7.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and -6.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -5.88% and -11.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares movedread more...
Benzinga
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics (NASDAQ:VVOS) stockread more...
Benzinga
Vivos Therapeutics (NASDAQ:VVOS) held its second-quarter earnings conference call on Friday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data andread more...
Benzinga
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.